Physician profile
Nancy Lamb
NPI 1326140047
$4,762.32
in general payments reported to CMS, 2019-2025
38 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 78% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $53.78 · 2021: $1,075 · 2022: $703 · 2023: $489 · 2024: $774 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735 · Education: $21.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.97 |
| Education | $21.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,973.35 | 2021-2025 | |
| Csl Behring | $239.07 | 2021-2025 | Hizentra |
| Pfizer INC. | $237.29 | 2023-2025 | |
| Lilly USA, LLC | $155.15 | 2021-2025 | Emgality, Zepbound, Reyvow |
| Forte Bio-Pharma LLC | $143.65 | 2025 | Tanlor |
| Biogen, INC. | $138.88 | 2021-2023 | Vumerity |
| Amgen INC. | $132.89 | 2024 | Uplizna |
| Sk Life Science, INC. | $127.52 | 2024-2025 | |
| Argenx US, INC. | $124.45 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $110.68 | 2023-2025 | Vyepti, Rexulti |
| Eisai INC. | $104.32 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $81.93 | 2022-2023 | Ongentys, Ingrezza |
| Sunovion Pharmaceuticals INC. | $81.19 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $74.24 | 2023 | Acthar |
| Ucb, INC. | $71.29 | 2022-2025 | Briviact |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.